Roivant Sciences ROIV
NASDAQ ROIV
$41.89 +0.41 (+0.99%)
As of: Sep 9, 2026 · 11:53 AM EDT

Roivant Sciences (ROIV) Profit After Tax (2020 - 2026)

Roivant Sciences' (ROIV) quarterly Profit After Tax came in at -$290.6 million in Q2 2026, down 6.1% on a YoY basis from -$309.5 million in Q2 2025, and up 61.44% quarter-over-quarter from -$753.7 million in Q4 2025.

Analysis

Roivant Sciences (ROIV) Profit After Tax (2020 - 2026) Analysis & Trends

Roivant Sciences (ROIV) has reported Profit After Tax for 7 consecutive years, with -$290.6 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Profit After Tax fell 6.1% year-over-year to -$290.6 million; the trailing twelve-month figure through Jun 2026 stood at -$1.5 billion (down 52.43% YoY), and the FY2026 full-year result was -$397.9 million, up 45.48% from the prior year.
  • Profit After Tax grew to -$290.6 million in Q2 2026 per ROIV's latest filing, from -$753.7 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $5.2 billion in Q4 2023 and bottomed at -$1.1 billion in Q4 2022.
  • Historically, Profit After Tax has averaged $41.7 million across 5 years, with a median of -$315.9 million in 2022.
  • The sharpest annual moves came in 2023 and 2025: Profit After Tax jumped 568.59% in 2023, then plunged 576.45% in 2025.
  • Over 5 years, Profit After Tax stood at -$1.1 billion in 2022, then surged by 568.59% to $5.2 billion in 2023, then tumbled by 109.26% to -$477.4 million in 2024, then tumbled by 57.88% to -$753.7 million in 2025, then soared by 61.44% to -$290.6 million in 2026.
  • According to Business Quant data, Profit After Tax over the past three periods registered -$290.6 million, -$753.7 million, and -$166.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT (Qtr)
1 Amgen 212.13 Bn 198.14 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 181.95 Bn 178.77 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 132.50 Bn 124.65 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 82.67 Bn 74.68 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 61.55 Bn 56.37 Bn 1.37 Bn 472.00 Mn
6 Moderna 54.65 Bn 49.51 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 34.23 Bn 30.92 Bn 992.69 Mn 164.49 Mn
8 Biogen 31.46 Bn 30.18 Bn 1.96 Bn 97.50 Mn
9 Roivant Sciences 30.19 Bn 30.19 Bn 1.16 Mn -290.61 Mn
10 Insmed 27.89 Bn 26.72 Bn 358.27 Mn -16.62 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -290.61 Mn
Dec 31, 2025 -753.70 Mn
Sep 30, 2025 -166.04 Mn
Jun 30, 2025 -273.91 Mn
Dec 31, 2024 -477.40 Mn
Sep 30, 2024 -279.92 Mn
Jun 30, 2024 57.49 Mn
Dec 31, 2023 5.15 Bn
Sep 30, 2023 -331.12 Mn
Jun 30, 2023 -327.85 Mn
Dec 31, 2022 -1.10 Bn
Sep 30, 2022 -315.92 Mn
Jun 30, 2022 -353.78 Mn
Dec 31, 2021 -632.80 Mn
Sep 30, 2021 -225.64 Mn
Jun 30, 2021 -101.08 Mn
Dec 31, 2020 -275.60 Mn
Sep 30, 2020 -53.50 Mn
Jun 30, 2020 -7.98 Mn